Skip to Content

A clinical trial of recombinant alkaline phosphatase infusion in sepsis-associated acute kidney injury (AKI)

Site-PI: Raghavan Murugan, MD

Funding: AM Pharma

Sepsis is a leading cause of AKI and is associated with increased risk of death. Alkaline phosphatase is an endogenous enzyme present in many cells and organs that exerts detoxifying effects through dephosphorylation of endotoxins including extracellular adenosine triphosphate. There is increasing evidence that the protein plays a significant role in host defense and innate immunity, particularly against inflammatory reactions due to lipopolysaccharide (LPS) release. Dr. Murugan is a site investigator for this multicenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, proof of concept, and dose-finding adaptive phase 2a/2b study to investigate the safety, tolerability and efficacy and effect on quality of life of human recombinant alkaline phosphatase in the treatment of patients with sepsis-associated AKI.